Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Cantor Fitzgerald
Julphar
Johnson and Johnson
US Department of Justice
Merck
Covington
Baxter
Fuji

Generated: November 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 200796

« Back to Dashboard

NDA 200796 describes EDARBI, which is a drug marketed by Arbor Pharms Llc and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the EDARBI profile page.

The generic ingredient in EDARBI is azilsartan kamedoxomil. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the azilsartan kamedoxomil profile page.
Summary for 200796
Tradename:EDARBI
Applicant:Arbor Pharms Llc
Ingredient:azilsartan kamedoxomil
Patents:3
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 200796
Generic Entry Date for 200796*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 200796
Suppliers and Packaging for NDA: 200796
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EDARBI azilsartan kamedoxomil TABLET;ORAL 200796 NDA Arbor Pharmaceuticals 60631-040 60631-040-07 5 BLISTER PACK in 1 TRAY (60631-040-07) > 7 TABLET in 1 BLISTER PACK
EDARBI azilsartan kamedoxomil TABLET;ORAL 200796 NDA Arbor Pharmaceuticals 60631-040 60631-040-30 30 TABLET in 1 BOTTLE (60631-040-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 40MG MEDOXOMIL
Approval Date:Feb 25, 2011TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:May 22, 2025Product Flag?Substance Flag?YDelist Request?
Patent:➤ Try a Free TrialPatent Expiration:Jan 7, 2025Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF HYPERTENSION
Patent:➤ Try a Free TrialPatent Expiration:Mar 26, 2028Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 200796

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-001 Feb 25, 2011 ➤ Try a Free Trial ➤ Try a Free Trial
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-002 Feb 25, 2011 ➤ Try a Free Trial ➤ Try a Free Trial
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-002 Feb 25, 2011 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Dow
Farmers Insurance
US Army
Mallinckrodt
McKesson
Colorcon
Fish and Richardson
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.